Medicago Planning Vaccine Production Facility in Durham, North Carolina
08/10/2010
"North Carolina's quality of work force, its training programs, and overall understanding of biotech development models were critical factors in our decision to locate in RTP," said Andy Sheldon, president and CEO of Medicago. "We are thrilled with our decision to build our vaccine facility in one of the largest and successful technology parks."
Medicago has received a $21 million research grant from the Defense Advanced Research Projects Agency (DARPA) to improve the production process of H1N1 vaccines. The company's project represents a total investment of more than $32 million in Research Triangle Park.
Project Announcements
Modus21 Expands North Charleston, South Carolina, Operations
12/10/2025
Lexington Manufacturing Plans Prineville, Oregon, Manufacturing Operations
12/10/2025
NOOTER Establishes Perrysburg, Ohio, Operations
12/10/2025
Cornerstone Building Brands Expands Rocky Mount, Virginia, Production Operations
12/10/2025
BWC Terminals Plans Pascagoula, Mississippi, Terminal Operations
12/10/2025
Farm Plast Plans Muncy, Pennsylvania, Manufacturing Operations
12/09/2025
Most Read
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025
-
How Canada Stays Competitive
Q3 2025
-
America’s Aerospace Reboot
Q3 2025
-
The Permit Puzzle and the Path to Groundbreaking
Q3 2025
-
2025’s Top States for Business: How the Winners Are Outpacing the Rest
Q3 2025